12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Indoximod: Phase II started

NewLink began a double-blind, placebo-controlled Phase II trial to compare 1,200 mg oral indoximod twice daily for the first 2 weeks of a 21-day...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >